Table 1.
RESONANCE population description.
| Characteristics | Prevalent cases | Incident cases | Total | ||||||
| Total participants, n (%) | 7018 (26.3) | 19,645 (73.7) | 26,663 (100) | ||||||
| Demography | |||||||||
|
|
Sex, n (%) | ||||||||
|
|
|
Male | 4241 (60.4) | 11,249 (57.3) | 15,490 (58.1) | ||||
|
|
|
Female | 2777 (39.6) | 8396 (42.7) | 11,173 (41.9) | ||||
|
|
Age at CLDa diagnosis, mean (SD) | 58.2 (14.8) | 60.5 (18.2) | 59.9 (17.4) | |||||
|
|
Death over follow-up, n (%) | 2438 (34.7) | 7778 (39.6) | 10,216 (38.3) | |||||
|
|
Hepatic cause of death over follow-up, n (%) | 1084 (44.5) | 2811 (36.1) | 3895 (38.1) | |||||
|
|
Unknown cause of death, n (%) | 237 (9.7) | 633 (8.1) | 870 (8.5) | |||||
|
|
Length of follow-up, mean (SD) | 105.5 (35.5) | 45.6 (33.2) | 61.4 (42.9) | |||||
|
|
Length of observation before CLD diagnosis, mean (SD) | 24 (0) | 64.6 (24.2) | 53.9 (27.4) | |||||
| Causes identified over follow-up, n (%) | |||||||||
|
|
MASLDb (large version) | 733 (10.4) | 6030 (30.7) | 6763 (25.4) | |||||
|
|
ALDc or MetALDd (large version) | 2915 (41.5) | 6071 (30.9) | 8986 (33.7) | |||||
|
|
Viral hepatitis identified | 1603 (22.8) | 1191 (6.1) | 2794 (10.5) | |||||
|
|
|
Viral hepatitis C | 2497 (35.6) | 1552 (7.9) | 4049 (15.2) | ||||
|
|
|
Viral hepatitis B (all) | 853 (12.2) | 995 (5.1) | 1848 (6.9) | ||||
|
|
|
Viral hepatitis B (with delta) | 63 (0.9) | 52 (0.3) | 115 (0.4) | ||||
|
|
Rare disease (all) | 587 (8.4) | 903 (4.6) | 1490 (5.6) | |||||
|
|
Hemochromatosis | 169 (2.4) | 367 (1.9) | 536 (2) | |||||
|
|
Wilson disease | 26 (0.4) | 17 (0.1) | 43 (0.2) | |||||
|
|
Primary biliary cholangitis | 238 (3.4) | 156 (0.8) | 394 (1.5) | |||||
|
|
Autoimmune hepatitis | 121 (1.7) | 168 (0.9) | 289 (1.1) | |||||
|
|
Primary sclerosing cholangitis | 49 (0.7) | 119 (0.6) | 168 (0.6) | |||||
|
|
Budd-Chiari syndrome | 19 (0.3) | 40 (0.2) | 59 (0.2) | |||||
|
|
Other | 13 (0.3) | 84 (0.4) | 107 (0.4) | |||||
| Main etiology identified over follow-up , n (%) | |||||||||
|
|
ALD | 978 (13.9) | 2671 (13.6) | 3649 (13.7) | |||||
|
|
MASLD | 572 (8.2) | 6030 (30.7) | 6602 (24.8) | |||||
|
|
MetALD | 1105 (15.7) | 2826 (14.4) | 3931 (14.7) | |||||
|
|
Mixed cause | 1592 (22.7) | 1303 (6.6) | 2895 (10.9) | |||||
|
|
Rare disease alone | 304 (4.3) | 535 (2.7) | 839 (3.1) | |||||
|
|
Viral cause alone | 1861 (26.5) | 1589 (8.1) | 3450 (12.9) | |||||
|
|
Unknown | 606 (8.6) |
4691 (23.9) |
5297 (19.9) |
|||||
| Risk factors identified over follow-up, n (%) | |||||||||
|
|
Alcohol-related condition or treatment | 2766 (39.4) | 6071 (30.9) | 8837 (33.1) | |||||
|
|
Tobacco-related condition or treatment | 2841 (40.5) | 7509 (38.2) | 10,350 (38.8) | |||||
|
|
Obesity | 1337 (19.1) | 5140 (26.2) | 6477 (24.3) | |||||
|
|
Type 2 diabetes | 1437 (20.5) | 4892 (24.9) | 6329 (23.7) | |||||
|
|
Hypertension | 3954 (56.3) | 11,485 (58.5) | 15,439 (57.9) | |||||
|
|
Dyslipidemia | 1630 (23.2) | 6031 (30.7) | 7661 (28.7) | |||||
|
|
Metabolic syndrome | 724 (10.3) | 2762 (14.1) | 3486 (13.1) | |||||
|
|
Sleep apnea syndrome | 612 (8.7) | 2449 (12.5) | 3061 (11.5) | |||||
|
|
Primary liver cancer | 932 (13.3) | 2032 (10.3) | 2964 (11.1) | |||||
| Charlson score when entering the cohort, mean (SD) | |||||||||
|
|
Standard (with liver diseases) | 3 (2.7) | 4.3 (3.3) | 4 (3.2) | |||||
|
|
Modified (excepting liver diseases) | 1.3 (2.1) | 2.3 (2.7) | 2 (2.6) | |||||
| Social environment and medical management at inclusion, n (%) | |||||||||
|
|
French Deprivation Index quintile of the municipality of residence | ||||||||
|
|
|
1 (least deprived) | 1259 (17.9) | 3217 (16.4) | 4476 (16.8) | ||||
|
|
|
2 | 1210 (17.2) | 3410 (17.4) | 4620 (17.3) | ||||
|
|
|
3 | 1441 (20.5) | 3651 (18.6) | 5092 (19.1) | ||||
|
|
|
4 | 1372 (19.5) | 4019 (20.5) | 5391 (20.2) | ||||
|
|
|
5 (most deprived) | 1533 (21.8) | 4537 (23.1) | 6070 (22.8) | ||||
|
|
—e | 203 (2.9) | 811 (4.1) | 1014 (3.8) | |||||
|
|
Access to primary care of the municipality of residence | ||||||||
|
|
|
Low | 519 (7.4) | 1967 (10) | 2486 (9.3) | ||||
|
|
|
Intermediate | 2635 (37.5) | 8171 (41.6) | 10,806 (40.5) | ||||
|
|
|
Good | 3728 (53.1) | 9192 (46.8) | 12,920 (48.5) | ||||
|
|
|
— e | 136 (1.9) | 315 (1.6) | 451 (1.7) | ||||
|
|
LTCf full coverage except CLD | 3393 (48.3) | 11,658 (59.3) | 15,051 (56.4) | |||||
|
|
Referring physician declared | 4033 (57.5) | 14,593 (74.3) | 18,626 (69.9) | |||||
| Medical management during follow-up, n (%) | |||||||||
|
|
LTC full coverage for CLD | 1880 (26.8) | 3250 (16.5) | 5130 (19.2) | |||||
|
|
Referring physician declared (at least one) | 6437 (91.7) | 17,637 (89.8) | 24,074 (90.3) | |||||
aCLD: chronic liver disease.
bMASLD: metabolic dysfunction–associated steatotic liver disease.
cALD: alcohol-related liver disease.
dMetALD: metabolic dysfunction–associated alcohol-related liver disease.
e Not available.
fLTC: long-term condition.